公开(公告)号：EP1453503A2

公开(公告)日：2004-09-08

申请号：EP02784629.4

申请日：2002-11-27

申请人： Merck & Co., Inc. ,  MERCK FROSST CANADA & CO.

发明人： OGIDIGBEN, Miller, J. ,  YOUNG, Robert, N. ,  BILLOT, Xavier ,  METTERS, Kathleen, M. ,  SLIPETZ, Deborah, M.

IPC分类号： A61K31/4015

CPC分类号： C07D403/12

摘要： This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.

公开(公告)号：EP1461026A2

公开(公告)日：2004-09-29

申请号：EP02784630.2

申请日：2002-11-27

申请人： Merck & Co., Inc. ,  MERCK FROSST CANADA INC.

发明人： OGIDIGBEN, Miller, J. ,  YOUNG, Robert, N. ,  METTERS, Kathleen, M. ,  SLIPETZ, Deborah, M. ,  BILLOT, Xavier

IPC分类号： A61K31/16 ,  A61K31/40 ,  A61K31/41 ,  A61K31/215

CPC分类号： A61K45/06 ,  A61K9/0048 ,  A61K31/4015 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/559 ,  A61K2300/00

摘要： This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions that are related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

公开(公告)号：EP1515722A2

公开(公告)日：2005-03-23

申请号：EP03739192.7

申请日：2003-06-17

申请人： Merck & Co., Inc. ,  BANYU PHARMACEUTICAL CO., LTD.

发明人： OGIDIGBEN, Miller, J. ,  YAMAKAWA, Takeru ,  SAGARA, Yufu

IPC分类号： A61K31/4545 ,  C07D401/14 ,  C07D405/14 ,  C07D417/14 ,  C07D409/14

CPC分类号： C07D271/107 ,  C07D235/26 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D495/04

摘要： This invention relates to selective m1 muscarinic agonist, their use or a formulation thereof in the treatment of glaucoma and/or other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans. In addition, the present invention relates to the use of the compounds in the treatment of dementia such as Alzheimer's disease and vascular dementia, depression, attention deficit disorder, sleep disorder, schizophrenia, pain, ischemia, atrophic gastritis, and atony of gastrointestinal tract.